Table 1 Baseline characteristics of the Patients^a

Age, years

65.37 ± 10.44

63.69 ± 10.40

68.85 ± 9.68

 Age ≥ 65 years, n (%)

222 (58.70%)

131 (51.40%)

91 (74.00%)

Male, n (%)

215 (56.90%)

156 (61.20%)

59 (48.00%)

BMI, kg/m²

24.43 ± 3.08

24.07 ± 3.00

25.17 ± 3.15

 Paroxysmal, n (%)

168 (44.40%)

128 (50.20%)

40 (32.50%)

 Persistent, n (%)

210 (55.60%)

127 (49.80%)

87 (67.50%)

Duration of AF, months

32.11 ± 44.82

33.44 ± 48.54

29.37 ± 35.91

Hypertension, n (%)

223 (59.00%)

141 (55.30%)

82 (66.70%)

 Systolic BP, mmHg

135.17 ± 20.83

134.39 ± 21.27

136.80 ± 19.88

 Diastolic BP, mmHg

82.94 ± 51.28

81.76 ± 42.34

85.39 ± 66.21

Diabetes, n (%)

56 (14.80%)

30 (11.80%)

26 (21.10%)

 FBG, mmol/L

5.14 ± 1.15

5.09 ± 1.02

5.26 ± 1.39

History of HF, n (%)

46 (12.20%)

20 (7.80%)

26 (21.10%)

Left ventricular EF, %

63.48 ± 7.52

63.82 ± 7.35

62.78 ± 7.85

Left atrial dimension, mm

40.82 ± 6.41

39.50 ± 5.72

43.56 ± 6.91

Left atrial ≥50 mm, n (%)

39 (10.30%)

13 (5.10%)

26 (21.10%)

Moderate valvular heart disease, n (%)

6 (1.60%)

3 (1.20%)

3 (2.40%)

CAD, n (%)

26 (6.90%)

12 (4.70%)

14 (11.40%)

Prior Stroke/TIA, n (%)

49 (13.00%)

31 (12.20%)

18 (14.60%)

CHADS2 Score

1.34 ± 1.19

1.17 ± 1.10

1.71 ± 1.30

CHA2DS2-VASc Score

2.81 ± 1.81

2.49 ± 1.70

3.48 ± 1.83

HAS-BLED Score

2.47 ± 1.06

2.32 ± 1.02

2.79 ± 1.07

CRP within 24 h post-procedure, mg/dL

6.36 ± 10.27

6.38 ± 10.87

6.32 ± 8.94

 Warfarin, n (%)

297 (78.57%)

194 (76.10%)

103 (83.70%)

 Dabigatran, n (%)

73 (19.31%)

54 (21.20%)

19 (15.40%)

 Xa inhibitor, n (%)

8 (2.12%)

7 (2.70%)

1 (0.80%)

Statins, n (%)

269 (71.20%)

174 (68.20%)

95 (77.20%)

ACEI/ARB, n (%)

169 (44.70%)

103 (40.40%)

66 (53.70%)

Beta-blockers, n (%)

111 (29.40%)

70 (27.50%)

41 (33.30%)

Vaughan Williams class I or III AAD, n (%)

342 (90.50%)

235 (92.20%)

107 (87.00%)

Amiodarone, n (%)

328 (86.80%)

228 (89.40%)

100 (81.30%)

Propafenon, n (%)

14 (3.70%)

7 (2.70%)

7 (5.70%)